AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20854144 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 600
Study 17646601 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 36
Study 17646601 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 36
Study 17646601 — intervention group
Group type: COMPARATOR
Intervention: UFH dosage of 5000 U 3 times daily
Number of subjects: 36
Study 17646601 — intervention group
Group type: COMPARATOR
Intervention: LMWH compared with UFH
Number of subjects: 36
Study 16287388 — intervention group
Group type: EXPERIMENTAL
Intervention: Secular forgiveness condition
Number of subjects: 192
Study 16287388 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious forgiveness condition
Number of subjects: 192
Study 16287388 — intervention group
Group type: COMPARATOR
Intervention: No-intervention comparison condition
Number of subjects: 192
Study 14607149 — intervention group
Group type: EXPERIMENTAL
Intervention: Facsimile Money
Number of subjects: 0
Study 14607149 — intervention group
Group type: COMPARATOR
Intervention: Real Money
Number of subjects: 0
Study 10665629 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20‐60 mg/day)
Number of subjects: 131
Study 10665629 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (50‐150 mg/day)
Number of subjects: 131
Study 10665629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (12 sessions)
Number of subjects: 131
Study 10665629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 8690817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg every 8 hours for 8 days) after a standardized 602-calorie, high-fat breakfast
Number of subjects: 20
Study 8690817 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir (1000 mg every 8 hours for 8 days) after an overnight fast
Number of subjects: 20
Study 2060542 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 30 mg/day
Number of subjects: 12
Study 2060542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6196822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 (1000-1500 ml) with Ringer's acetate solution (2000-3000 ml)
Number of subjects: 23
Study 6196822 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate alone (5000-8000 ml)
Number of subjects: 23
Study 6196822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 23
Study 6196822 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 23
Study 3515137 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 19
Study 3515137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31895166 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular statin users
Number of subjects: 2664
Study 31895166 — intervention group
Group type: COMPARATOR
Intervention: Nonregular statin users
Number of subjects: 2664
Study 31895166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic statin users
Number of subjects: 2664
Study 31895166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic statin users
Number of subjects: 2664
Study 27208982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 500
Study 27208982 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 500
Study 24710972 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sitting, standing, and walking in conjunction with contemporary Bobath approach (ECBA)
Number of subjects: 48
Study 24710972 — intervention group
Group type: COMPARATOR
Intervention: Contemporary Bobath approach (CBA)
Number of subjects: 48
Study 24085484 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirst-driven fluid intake (TD)
Number of subjects: 10
Study 24085484 — intervention group
Group type: COMPARATOR
Intervention: Programmed fluid intake (PFI)
Number of subjects: 10
Study 20150565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction (BFR) at 20% of 1-repetition maximum (1-RM) with pressure cuff inflated at 200 mmHg
Number of subjects: 7
Study 20150565 — intervention group
Group type: COMPARATOR
Intervention: Control group (exercise without pressure cuff)
Number of subjects: 7
Study 20150565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity resistance exercise with blood flow restriction (BFR)
Number of subjects: 7
Study 20150565 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity resistance exercise without blood flow restriction (Control)
Number of subjects: 7
Study 18603750 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane (Group B - BIS)
Number of subjects: 40
Study 18603750 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol (Group D - BIS)
Number of subjects: 40
Study 16514531 — intervention group
Group type: EXPERIMENTAL
Intervention: CTAC scans
Number of subjects: 107
Study 16514531 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET scans
Number of subjects: 107
Study 16514531 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic CT (gold standard)
Number of subjects: 107
Study 12562048 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 1130
Study 12562048 — intervention group
Group type: COMPARATOR
Intervention: 90 mg pamidronate
Number of subjects: 1130
Study 9836092 — intervention group
Group type: EXPERIMENTAL
Intervention: Life review intervention
Number of subjects: 256
Study 9836092 — intervention group
Group type: COMPARATOR
Intervention: Friendly visit (control)
Number of subjects: 256
Study 8009935 — intervention group
Group type: EXPERIMENTAL
Intervention: baclofen
Number of subjects: 90
Study 8009935 — intervention group
Group type: COMPARATOR
Intervention: sibazon
Number of subjects: 90
Study 8009935 — intervention group
Group type: COMPARATOR
Intervention: amitriptylin
Number of subjects: 90
Study 8009935 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 2492325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA, 150 mg/8 h)
Number of subjects: 40
Study 2492325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2492325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients with intracoronary thrombus
Number of subjects: 40
Study 2492325 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with intracoronary thrombus
Number of subjects: 40
Study 2492325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients without thrombus
Number of subjects: 40
Study 2492325 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients without thrombus
Number of subjects: 40
Study 1085563 — intervention group
Group type: EXPERIMENTAL
Intervention: Total shunt (mesorenal H graft)
Number of subjects: 46
Study 1085563 — intervention group
Group type: COMPARATOR
Intervention: Selective distal splenorenal (Warren) shunt
Number of subjects: 46
Study 31909482 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported non-coeliac wheat sensitivity (SR-NCWS) in 2015 (13.8%; 95% CI, 12.0-15.8%)
Number of subjects: 1322
Study 31909482 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident SR-NCWS reported between 2015 and 2018 (5.3% of respondents)
Number of subjects: 1322
Study 31909482 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten avoidance reported in 2018 (24.2% of respondents)
Number of subjects: 1322
Study 31909482 — intervention group
Group type: COMPARATOR
Intervention: Participants with coeliac disease
Number of subjects: 1322
Study 31909482 — intervention group
Group type: COMPARATOR
Intervention: Participants with irritable bowel syndrome
Number of subjects: 1322
Study 31909482 — intervention group
Group type: COMPARATOR
Intervention: Participants with functional dyspepsia
Number of subjects: 1322
Study 29978790 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT (radial extracorporeal shockwave therapy) for 1 cycle
Number of subjects: 40
Study 29978790 — intervention group
Group type: COMPARATOR
Intervention: Local hormone injection for 1 cycle
Number of subjects: 40
Study 26597879 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual intervention (psychotherapy)
Number of subjects: 90
Study 26597879 — intervention group
Group type: COMPARATOR
Intervention: Control group (breast cancer patients without intervention)
Number of subjects: 90
Study 25087182 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase and steroids
Number of subjects: 257
Study 25087182 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 257
Study 25087182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 257
Study 25087182 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of asparaginase and steroids
Number of subjects: 257
Study 25087182 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of ALL therapy
Number of subjects: 257
Study 22659709 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program about HIV/AIDS (two days' observation and one-day workshop)
Number of subjects: 0
Study 22659709 — intervention group
Group type: COMPARATOR
Intervention: Control group (students from Shahid Beheshti University of Medical Sciences)
Number of subjects: 0
Study 20636856 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic film array application of 5% urea gel
Number of subjects: 17
Study 20636856 — intervention group
Group type: COMPARATOR
Intervention: Passive occluded application of 5% urea gel with plastic occlusive film and non-magnetic film
Number of subjects: 17
Study 19068713 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional segmentectomy for clinical T1NOM0 NSCLC of 2 cm or less
Number of subjects: 0
Study 19068713 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 0
Study 19068713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediastinal lymph node dissection (MLND)
Number of subjects: 0
Study 15745837 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial strategy: premeal insulin lispro with basal insulin at bedtime (NPH insulin), targeting 2‐h PPBG < or = 7.5 mmol/l
Number of subjects: 1355
Study 15745837 — intervention group
Group type: COMPARATOR
Intervention: Basal strategy: insulin (NPH insulin twice daily or insulin glargine once daily; or premixed human insulin (70% NPH/30% regular; 30/70) twice daily), targeting fasting and premeal blood glucose (BG; < or = 6.7 mmol/l)
Number of subjects: 1355
Study 12600854 — intervention group
Group type: EXPERIMENTAL
Intervention: Harris‐Benedict equation
Number of subjects: 448
Study 12600854 — intervention group
Group type: EXPERIMENTAL
Intervention: FAO/WHO equation
Number of subjects: 448
Study 12600854 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 448
Study 12600854 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake adjustment
Number of subjects: 448
Study 12600854 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet composition, sex, race, age, baseline weight
Number of subjects: 448
Study 10427125 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic alterations detected by RLGS
Number of subjects: 21
Study 7569821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent in ADL
Number of subjects: 602
Study 7569821 — intervention group
Group type: COMPARATOR
Intervention: Independent in ADL
Number of subjects: 602
Study 7569821 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking speed
Number of subjects: 602
Study 7569821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sight impairment in men
Number of subjects: 602
Study 7569821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence developed between ages 70 and 76
Number of subjects: 602
Study 2268486 — intervention group
Group type: EXPERIMENTAL
Intervention: HD with a sodium profile (140‐148 mmol/L)
Number of subjects: 15
Study 2268486 — intervention group
Group type: EXPERIMENTAL
Intervention: HD with a sodium profile and a variable UF rate (high‐low UF rate)
Number of subjects: 15
Study 2268486 — intervention group
Group type: COMPARATOR
Intervention: Conventional HD (dialysate sodium 140 mmol/L)
Number of subjects: 15
Study 439926 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 263
Study 439926 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 263
Study 439926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 263
Study 31915861 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day of CBD for 1 week
Number of subjects: 32
Study 31915861 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 32
Study 31419355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible patients for phase III trials
Number of subjects: 1267
Study 31419355 — intervention group
Group type: COMPARATOR
Intervention: Non-eligible patients for phase III trials
Number of subjects: 1267
Study 29504579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibula fixation
Number of subjects: 130
Study 29504579 — intervention group
Group type: COMPARATOR
Intervention: Core decompression
Number of subjects: 130
Study 26706805 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (selective retrieval of macroscopic colorectal deep endometriosis nodules by bowel shaving and disc excision)
Number of subjects: 0
Study 26706805 — intervention group
Group type: COMPARATOR
Intervention: Radical approach (low large colorectal resection)
Number of subjects: 0
Study 26706805 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative approach
Number of subjects: 0
Study 25261342 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid antagonist (50 mg naltrexone)
Number of subjects: 58
Study 25261342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 25261342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both naltrexone and placebo after exercise
Number of subjects: 58
Study 22492479 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 6460
Study 20443645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential use of pharmacotherapy and psychotherapy
Number of subjects: 0
Study 20443645 — intervention group
Group type: COMPARATOR
Intervention: Clinical management and treatment as usual
Number of subjects: 0
Study 17876994 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine
Number of subjects: 0
Study 17876994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 0
Study 17876994 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0
Study 17876994 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine, paroxetine, and sertraline (SSRIs available in Japan)
Number of subjects: 0
Study 16128368 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (15,000 KIU/min) administered in the pulmonary artery
Number of subjects: 20
Study 16128368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12206997 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomoxir
Number of subjects: 0
Study 12206997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10566553 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum RCP levels in breast cancer patients
Number of subjects: 52
Study 10566553 — intervention group
Group type: EXPERIMENTAL
Intervention: RCP assay for breast cancer detection
Number of subjects: 52
Study 10566553 — intervention group
Group type: EXPERIMENTAL
Intervention: RCP level > or = 1.0 ng/ml
Number of subjects: 52
Study 8614913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 150
Study 8614913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 2006653 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 36
Study 2006653 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 36
Study 2006653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg plus Amiloride 2.5 mg
Number of subjects: 36
Study 2006653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7228648 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic screening (two screening sessions held about two years apart)
Number of subjects: 7229
Study 7228648 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical care (control group)
Number of subjects: 7229
Study 31397125 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture preconditioning combined with induced urination
Number of subjects: 80
Study 31397125 — intervention group
Group type: COMPARATOR
Intervention: Routine group (control)
Number of subjects: 80
Study 27003595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) over 3 months (12 weekly sessions)
Number of subjects: 31
Study 27003595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific LUTS treatment)
Number of subjects: 31
Study 27003595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 31
Study 27856482 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-month training programme for nurses
Number of subjects: 34
Study 24731890 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week stress management programme (relaxation breathing and progressive muscle relaxation, RB-PMR, twice a day) (N=31)
Number of subjects: 60
Study 24731890 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the stress management programme) (N=29)
Number of subjects: 60
Study 23208898 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI plus MRS group
Number of subjects: 20
Study 23208898 — intervention group
Group type: COMPARATOR
Intervention: MRI group
Number of subjects: 20
Study 20655946 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Towards No Drug Abuse (TND) program with regular workshop training
Number of subjects: 2538
Study 20655946 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Towards No Drug Abuse (TND) program with comprehensive implementation support
Number of subjects: 2538
Study 20655946 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 2538
Study 17434541 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg cinnarizine (CIN)
Number of subjects: 12
Study 17434541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocculus Indicus 6CH (COC)
Number of subjects: 12
Study 17434541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 12
Study 15865915 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level white noise generators (NG)
Number of subjects: 124
Study 15865915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT)
Number of subjects: 124
Study 11956258 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF (epirubicin 50 mg/m(2) every 3 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 200 mg/m(2)/d)
Number of subjects: 580
Study 11956258 — intervention group
Group type: COMPARATOR
Intervention: MCF (mitomycin 7 mg/m(2) every 6 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 300 mg/m(2)/d)
Number of subjects: 580
Study 11956258 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF
Number of subjects: 580
Study 11956258 — intervention group
Group type: COMPARATOR
Intervention: MCF
Number of subjects: 580
Study 9708225 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day etidronate for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Number of subjects: 49
Study 9708225 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Number of subjects: 49
Study 9708225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received calcium and vitamin D supplementation
Number of subjects: 49
Study 8374234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular cataract extraction (ICCE) with Choyce‐IX anterior chamber lens (ACL)
Number of subjects: 65
Study 8374234 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (ECCE) with posterior chamber lens (PCL)
Number of subjects: 65
Study 2437556 — intervention group
Group type: EXPERIMENTAL
Intervention: Placenta eluted IgG
Number of subjects: 113
Study 2437556 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoglobulins
Number of subjects: 113
Study 2437556 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 113
Study 29911321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2-laser treatment (two sessions in a 4-week interval)
Number of subjects: 26
Study 29911321 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated skin graft)
Number of subjects: 26
Study 29911321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2-laser treatment
Number of subjects: 26
Study 28901116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides combined with Danshen injection
Number of subjects: 0
Study 28901116 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 0
Study 25239537 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Clinical Question Recorder
Number of subjects: 904
Study 25239537 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence Retrieval Coach (eight short educational videos)
Number of subjects: 904
Study 25239537 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit, Feedback and Gamification approach
Number of subjects: 904
Study 25239537 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 904
Study 23158080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygienic-dietary recommendations (active lifestyle recommendations)
Number of subjects: 300
Study 23158080 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 300
Study 20137366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with sufentanil 0.5 microg/ml
Number of subjects: 450